Literature DB >> 24471911

Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey.

Massimo Marignani1, Alfredo Marzano, Paola Begini, Umberto Vitolo, Stefano Luminari, Alessandro Levis, Ilaria Deli, Elia Gigante, Emanuela De Santis, Gianfranco delle Fave, Bruno Monarca, Maria Christina Cox.   

Abstract

Hepatitis B virus (HBV) reactivation strongly affects the practice of physicians dealing with hematological malignancies. In this respect, in collaboration with the Italian Lymphoma Foundation we developed a descriptive study of the real-life approach of physicians caring for patients with these diseases. A questionnaire was designed to explore the perception of HBV reactivation-related issues. Fifty-nine Italian Lymphoma Foundation-affiliated institutions participated, and 504 questionnaires were sent out. Forty institutions (67.8%) returned 154 (30.5%) completed questionnaires. The largest majority (91.5%, 141/154) were aware of possible HBV reactivation as a consequence of immunosuppression. Most of the participants providing an answer (93.3%; 126/135) performed universal screening, and were aware of strategies for managing reactivation (96.4%, 132/137). Specialists treating lymphoma show a high level of awareness concerning the management of HBV reactivation under immunosuppression. However, uncertainties regarding the issue of HBV reactivation still emerge in this setting, and thus continuing collaborative effort between hepatologists and hematologists is necessary.

Entities:  

Keywords:  HBV; HBV reactivation; Hodgkin lymphoma; hematologic malignancies; immunosuppression; non-Hodgkin lymphoma

Mesh:

Year:  2014        PMID: 24471911     DOI: 10.3109/10428194.2013.879712

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy.

Authors:  Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

2.  HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience.

Authors:  Michele Clerico; Irene Dogliotti; Paola Ghione; Vittorio Ruggero Zilioli; Francesco Merli; Barbara Botto; Wael Al Essa; Marcella Battaglini; Daniele Grimaldi; Loretta Cervi; Simone Ragaini; Simone Ferrero; Veronica Peri; Gabriele De Luca; Alfredo Marzano; Federica Cavallo
Journal:  J Pers Med       Date:  2022-02-15

Review 3.  Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management.

Authors:  Alessandra Zannella; Massimo Marignani; Paola Begini
Journal:  Viruses       Date:  2019-09-14       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.